2560 Baseline serum clusterin level in patients with poor prognostic features was associated with response to custirsen treatment: Results from the phase 3 SYNERGY trial of docetaxel +/- custirsen
Year: 2015
Type: article
Source: European Journal of Cancer
Authors: J. De Bono, C. Higano, B. Blumenstein, S. Feyerabend, G. Gravis, J.M. Ferrero, C. Jacobs, K. Chi
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2507383942